secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0000921299-25-000007
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen completes sale of China business to AstraZeneca for ~$220M; repays $81M term loan
--------------------------------------------------------------------------------

- Sale price ~$220M: $85M enterprise value plus ~$135M net cash held in China.
- Net cash received $210.4M; transaction costs $7.7M; net assets sold $138.9M.
- Pro forma cash and equivalents rise to $145M from $23M; pro forma deficit narrows to $1.684B.
- Repaid $80.9M to MSTV, including $73.7M term loan balance and $6.8M loss on debt extinguishment.
- Released $142.9M deferred revenue related to China single performance obligation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/0000921299-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/fgen-20250829.htm
  HTML page:      https://secwatch.observer/filing/0000921299-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer